BET Inhibitor

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

neoplasms, in addition to the above: small cell lung cancer, BRCA1/2 wild type ovarian cancer advanced solid tumours cancer

Unknown Phase

A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and;Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors

Active, not recruitingNL-OMON46213

Bristol-Myers Squibbneoplasms, in addition to the above: small cell lung cancer, BRCA1/2 wild type ovarian cancer advanced solid tumours cancer

Start: 2016-11-01Target: 12Updated: 2024-02-28

Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor

Bristol-Myers Squibb

Updated: 2022-10-14